FDA Qualifies MolecuLightDX as Medical Device Development Tool for Wound Care Innovation
核心洞察
MolecuLight (搜索)'s MolecuLightDX (搜索) wound measurement technology received FDA qualification as a Medical Device Development Tool (MDDT), joining only 20 tools granted this designation since 2017.
The MDDT qualification validates MolecuLightDX (搜索) as a response biomarker for regulatory use, enabling objective evaluation of treatment effectiveness in wound healing studies.
MolecuLightDX (搜索) becomes the only wound care (搜索) device with both FDA Class II clearance for clinical use and MDDT qualification, providing standardized measurement capabilities for clinical trials.
MolecuLight (搜索) announced that the U.S. Food and Drug Administration has qualified its MolecuLightDX (搜索) wound measurement technology as a Medical Device Development Tool (MDDT), marking a significant milestone for wound care (搜索) research and development. The FDA's MDDT program qualifies select, scientifically validated tools for use in medical device development and evaluation, enabling sponsors to generate reliable, FDA-accepted data in clinical investigations.
Regulatory Significance and Rarity
Since the MDDT program began in 2017, qualification has been granted to only 20 tools, including MolecuLightDX (搜索). This exclusive designation validates the MolecuLightDX quantitative wound measurement function for regulatory use as a response biomarker, supporting objective evaluation of treatment effectiveness and data generation that may be used in FDA clearance and approval decisions for new wound products.
MolecuLightDX (搜索) achieves a unique regulatory position as the only wound care (搜索) device that is both FDA Class II cleared for clinical use and FDA qualified as an MDDT. This dual status provides accurate, non-contact, and reproducible wound measurement images and data suitable for clinical trial endpoints across a variety of wound types.
Technology and Clinical Validation
The MolecuLightDX (搜索) system is a Class II FDA-cleared medical device designed for real-time detection and visualization of elevated bacterial loads (>10⁴ CFU/g) in wounds using proprietary fluorescence imaging technology. The device's performance is supported by the largest clinical validation study conducted in wound imaging, demonstrating consistent results across wound types, skin tones, and patient populations.
"The FDA's qualification of MolecuLightDX (搜索) as an MDDT reflects the strength of our clinical evidence and the agency's confidence in the accuracy and reproducibility of our wound measurement technology," said Anil Amlani, Chief Executive Officer of MolecuLight (搜索). "This designation enables researchers and sponsors to use MolecuLightDX as a standardized, trusted measurement tool in wound healing studies, accelerating innovation and improving patient outcomes."
Impact on Wound Care Development
The MDDT qualification positions MolecuLightDX (搜索) as a standardized measurement tool for wound healing studies, potentially accelerating the development and evaluation of new wound care (搜索) products. The designation allows researchers and sponsors to use the device with confidence that the generated data will meet FDA standards for regulatory submissions, streamlining the path from research to clinical application.